Clinical trial
Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic…
NCT00099255 · Seagen Inc., Industry · Completed
Key facts
| NCT number | NCT00099255 |
|---|---|
| Title | Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma |
| Official title | A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma, Large Cell Transformation of Mycosis Fungoides, and Lymphomatoid Papulosis |
| Lead sponsor | Seagen Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Large Cell Lymphoma |
| Intervention type | Drug |
| Interventions | SGN-30 |
| Enrollment | 40 |
| Start date | Sep 1, 2004 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Dec 10, 2004 |
| Last update posted | Dec 18, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: